{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:03:35Z","timestamp":1753891415013,"version":"3.41.2"},"reference-count":46,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,9,6]],"date-time":"2024-09-06T00:00:00Z","timestamp":1725580800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Microbiol."],"abstract":"<jats:p>Shigellosis remains a significant global health challenge, particularly in Asia and Africa, where it is a major cause of morbidity and mortality among children. Despite the urgent need, the development of a licensed <jats:italic>Shigella<\/jats:italic> vaccine has been hindered, partly due to the lack of suitable animal models for preclinical evaluation. In this study, we used an intragastric adult rhesus macaque challenge model to evaluate the safety, immunogenicity, and efficacy of five live-attenuated <jats:italic>Shigella dysenteriae<\/jats:italic> 1 vaccine candidates, all derived from the 1617 parent strain. The vaccine strains included WRSd1, a previously tested candidate with deletions in virG(icsA), stxAB, and fnr, and four other strains\u2014WRSd2, WRSd3, WRSd4, and WRSd5\u2014each containing deletions in virG and stxAB, but retaining fnr. Additionally, WRSd3 and WRSd5 had further deletions in the <jats:italic>Shigella<\/jats:italic> enterotoxin gene senA and its paralog senB, with WRSd5 having an extra deletion in msbB2. Rhesus monkeys were immunized three times at two-day intervals with a target dose of 2 \u00d7 10<jats:sup>10<\/jats:sup> CFU of the vaccine strains. Thirty days after the final immunization, all monkeys were challenged with a target dose of 2 \u00d7 10<jats:sup>9<\/jats:sup> CFU of the <jats:italic>S. dysenteriae<\/jats:italic> 1 1617 wild-type strain. Safety, immunogenicity, and efficacy were assessed through physical monitoring and the evaluation of immunologic and inflammatory markers following immunization and challenge. Initial doses of WRSd1, WRSd3, and WRSd5 led to mild adverse effects, such as vomiting and loose stools, but all five vaccine strains were well tolerated in subsequent doses. All strains elicited significant IgA and IgG antibody responses, as well as the production of antibody-secreting cells. Notably, none of the vaccinated animals exhibited shigellosis symptoms such as vomiting or loose\/watery stool post-challenge, in stark contrast to the control group, where 39% and 61% of monkeys exhibited these symptoms, respectively. The aggregate clinical score used to evaluate <jats:italic>Shigella<\/jats:italic> attack rates post-challenge revealed a 72% attack rate in control animals, compared to only 13% in vaccinated animals, indicating a relative risk reduction of 81%. This study highlights the potential of this NHP model in evaluating the safety, immunogenicity, and efficacy of live-attenuated <jats:italic>Shigella<\/jats:italic> vaccine candidates, offering a valuable tool for preclinical assessment before advancing to Phase 1 or more advanced clinical trials.<\/jats:p>","DOI":"10.3389\/fmicb.2024.1454338","type":"journal-article","created":{"date-parts":[[2024,9,6]],"date-time":"2024-09-06T10:25:55Z","timestamp":1725618355000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["A rhesus macaque intragastric challenge model for evaluating the safety, immunogenicity, and efficacy of live-attenuated Shigella dysenteriae 1 vaccine candidates"],"prefix":"10.3389","volume":"15","author":[{"given":"Nattaya","family":"Ruamsap","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rawiwan","family":"Imerbsin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patchariya","family":"Khanijou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siriphan","family":"Gonwong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wilawan","family":"Oransathit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shoshana","family":"Barnoy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Malabi M.","family":"Venkatesan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sidhartha","family":"Chaudhury","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dilara","family":"Islam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2024,9,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1177\/2051013613500428","article-title":"An update on vaccines against Shigella","volume":"1","author":"Ashkenazi","year":"2013","journal-title":"Ther. Adv. Vaccines."},{"key":"B2","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1128\/cdli.2.4.492-495.1995","article-title":"Cytokines in the stools of children with complicated shigellosis","volume":"2","author":"Azim","year":"1995","journal-title":"Clin. Diagn. Lab. Immunol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1038\/nrgastro.2013.12","article-title":"Progress and pitfalls in Shigella vaccine research","volume":"10","author":"Barry","year":"2013","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"103308","DOI":"10.1016\/j.ebiom.2021.103308","article-title":"Immune response characterization in a human challenge study with a Shigella flexneri 2a bioconjugate vaccine","volume":"66","author":"Clarkson","year":"2021","journal-title":"EBioMedicine."},{"key":"B5","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1016\/S1473-3099(20)30488-6","article-title":"Safety and immunogenicity of a synthetic carbohydrate conjugate vaccine against Shigella flexneri 2a in healthy adult volunteers: a phase 1, dose-escalating, single-blind, randomised, placebo-controlled study","volume":"21","author":"Cohen","year":"2021","journal-title":"Lancet Infect. Dis."},{"key":"B6","doi-asserted-by":"publisher","first-page":"3437","DOI":"10.1128\/IAI.67.7.3437-3443.1999","article-title":"Vaccination against shigellosis with attenuated Shigella flexneri 2a strain SC602","volume":"67","author":"Coster","year":"1999","journal-title":"Infect. Immun."},{"key":"B7","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1136\/gut.34.2.194","article-title":"Concentrations of interleukin 6 and tumour necrosis factor in serum and stools of children with Shigella dysenteriae 1 infection","volume":"34","author":"de Silva","year":"1993","journal-title":"Gut."},{"key":"B8","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1046\/j.1365-2672.2000.00841.x","article-title":"A rapid DNA isolation procedure for the identification of Campylobacter jejuni by the polymerase chain reaction","volume":"31","author":"Englen","year":"2000","journal-title":"Lett. Appl. Microbiol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/BF01640829","article-title":"The differential leukocyte count in shigellosis","volume":"10","author":"Fried","year":"1982","journal-title":"Infection."},{"key":"B10","doi-asserted-by":"publisher","first-page":"340","DOI":"10.3390\/vaccines10020340","article-title":"Evaluation of the safety, tolerability and immunogenicity of ShigETEC, an oral live attenuated Shigella-ETEC vaccine in placebo-controlled randomized phase 1 trial","volume":"10","author":"Girardi","year":"2022","journal-title":"Vaccines"},{"key":"B11","doi-asserted-by":"publisher","first-page":"2027","DOI":"10.1128\/IAI.01665-13","article-title":"Development of an Aotus nancymaae model for Shigella vaccine immunogenicity and efficacy studies","volume":"82","author":"Gregory","year":"2014","journal-title":"Infect. Immun."},{"key":"B12","doi-asserted-by":"publisher","first-page":"205","DOI":"10.3109\/00365549209052613","article-title":"The differential leukocyte count in adults with acute gastroenteritis","volume":"24","author":"Halpern","year":"1992","journal-title":"Scand. J. Infect. Dis."},{"key":"B13","doi-asserted-by":"publisher","first-page":"4075","DOI":"10.1128\/iai.59.11.4075-4083.1991","article-title":"Small-animal model to measure efficacy and immunogenicity of Shigella vaccine strains","volume":"59","author":"Hartman","year":"1991","journal-title":"Infect. Immun."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1128\/jb.172.4.1905-1915.1990","article-title":"Sequence and molecular characterization of a multicopy invasion plasmid antigen gene, ipaH, of Shigella flexneri","volume":"172","author":"Hartman","year":"1990","journal-title":"J. Bacteriol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"3762","DOI":"10.1016\/j.vaccine.2005.07.023","article-title":"Establishment of a non-human primate Campylobacter disease model for the preclinical evaluation of Campylobacter vaccine formulations","volume":"24","author":"Islam","year":"2006","journal-title":"Vaccine"},{"key":"B16","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1111\/imm.12549","article-title":"Controlling the cytokine storm in severe bacterial diarrhoea with an oral Toll-like receptor 4 antagonist","volume":"147","author":"Islam","year":"2016","journal-title":"Immunology"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0294021","article-title":"Bioactivity and efficacy of a hyperimmune bovine colostrum product-Travelan, against shigellosis in a non-Human primate model (Macaca mulatta)","author":"Islam","year":"2023","journal-title":"PLoS ONE"},{"key":"B18","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1111\/apm.12168","article-title":"Evaluation of an intragastric challenge model for Shigella dysenteriae 1 in rhesus monkeys (Macaca mulatta) for the preclinical assessment of Shigella vaccine formulations","volume":"122","author":"Islam","year":"2014","journal-title":"APMIS."},{"key":"B19","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1128\/IAI.72.2.923-930.2004","article-title":"Two studies evaluating the safety and immunogenicity of a live, attenuated Shigella flexneri 2a vaccine (SC602) and excretion of vaccine organisms in North American volunteers","volume":"72","author":"Katz","year":"2004","journal-title":"Infect. Immun."},{"key":"B20","doi-asserted-by":"publisher","first-page":"2016","DOI":"10.1128\/IAI.70.4.2016-2021.2002","article-title":"Phase I evaluation of delta virG Shigella sonnei live, attenuated, oral vaccine strain WRSS1 in healthy adults","volume":"70","author":"Kotloff","year":"2002","journal-title":"Infect. Immun."},{"key":"B21","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1128\/ecosalplus.ESP-0006-2017","article-title":"A brief history of Shigella","volume":"8","author":"Lampel","year":"2018","journal-title":"Eco. Sal. Plus."},{"key":"B22","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1186\/1741-7007-8-129","article-title":"Immunogenicity and efficacy of oral vaccines in developing countries: lessons from a live cholera vaccine","volume":"8","author":"Levine","year":"2010","journal-title":"BMC Biol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1093\/infdis\/127.3.261","article-title":"Pathogenesis of Shigella dysenteriae 1 (Shiga) dysentery","volume":"127","author":"Levine","year":"1973","journal-title":"J. Infect. Dis."},{"key":"B24","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/0264-410x(93)90016-q","article-title":"Evaluation of Shigella vaccine safety and efficacy in an intranasally challenged mouse model","volume":"11","author":"Mallett","year":"1993","journal-title":"Vaccine"},{"key":"B25","doi-asserted-by":"publisher","first-page":"2887","DOI":"10.1016\/j.vaccine.2016.02.075","article-title":"Status of vaccine research and development for Shigella","volume":"34","author":"Mani","year":"2016","journal-title":"Vaccine."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1046\/j.1365-2958.1999.01669.x","article-title":"Spontaneous tandem amplification and deletion of the shiga toxin operon in Shigella dysenteriae 1","volume":"34","author":"McDonough","year":"1999","journal-title":"Mol. Microbiol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"3291","DOI":"10.1016\/j.vaccine.2008.03.079","article-title":"Safety and immunogenicity of WRSd1, a live attenuated Shigella dysenteriae type 1 vaccine candidate","volume":"26","author":"McKenzie","year":"2008","journal-title":"Vaccine."},{"key":"B28","doi-asserted-by":"publisher","first-page":"927","DOI":"10.4269\/ajtmh.1971.20.927","article-title":"Epidemic Shiga-bacillus dysentery in Central America. Derivation of the epidemic and its progression in Guatemala, 1968-69","volume":"20","author":"Mendizabal-Morris","year":"1971","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines10020328","article-title":"Towards a four-component GMMA-based vaccine against Shigella","author":"Micoli","year":"2022","journal-title":"Vaccines (Basel)"},{"key":"B30","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1128\/cdli.3.2.242-245.1996","article-title":"Antibody response of monkeys to invasion plasmid antigen D after infection with Shigella spp","volume":"3","author":"Oaks","year":"1996","journal-title":"Clin. Diagn. Lab. Immunol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1128\/iai.48.1.124-129.1985","article-title":"Plaque formation by virulent Shigella flexneri","volume":"48","author":"Oaks","year":"1985","journal-title":"Infect. Immun."},{"key":"B32","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1093\/clinchem\/44.9.2057","article-title":"Multiplexed analysis of human cytokines by use of the FlowMetrix system","volume":"44","author":"Oliver","year":"1998","journal-title":"Clin. Chem."},{"key":"B33","doi-asserted-by":"publisher","first-page":"8027","DOI":"10.1128\/IAI.73.12.8027-8032.2005","article-title":"Community-based safety, immunogenicity, and transmissibility study of the Shigella sonnei WRSS1 vaccine in Israeli volunteers","volume":"73","author":"Orr","year":"2005","journal-title":"Infect. Immun."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.3390\/pathogens10091079","article-title":"Evaluation of a live attenuated S. sonnei vaccine strain in the human enteroid model","volume":"10","author":"Pilla","year":"2021","journal-title":"Pathogens"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1016\/j.vaccine.2010.10.035","article-title":"Safety, dose, immunogenicity, and transmissibility of an oral live attenuated Shigella flexneri 2a vaccine candidate (SC602) among healthy adults and school children in Matlab, Bangladesh","volume":"29","author":"Rahman","year":"2011","journal-title":"Vaccine."},{"key":"B36","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1093\/infdis\/171.2.376","article-title":"Cytokine secretion in acute shigellosis is correlated to disease activity and directed more to stool than to plasma","volume":"171","author":"Raqib","year":"1995","journal-title":"J. Infect. Dis."},{"key":"B37","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1097\/MOG.0b013e32830007f7","article-title":"Host-bacteria homeostasis in the healthy and inflamed gut","volume":"24","author":"Sansonetti","year":"2008","journal-title":"Curr. Opin. Gastroenterol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"2476","DOI":"10.4049\/jimmunol.178.4.2476","article-title":"New animal model of shigellosis in the Guinea pig: its usefulness for protective efficacy studies","volume":"178","author":"Shim","year":"2007","journal-title":"J. Immunol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"4197","DOI":"10.4049\/jimmunol.173.6.4197","article-title":"IL-8 is a key chemokine regulating neutrophil recruitment in a new mouse model of Shigella-induced colitis","volume":"173","author":"Singer","year":"2004","journal-title":"J. Immunol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"548","DOI":"10.3390\/vaccines10040548","article-title":"From concept to clinical product: a brief history of the novel Shigella invaplex vaccine's refinement and evolution","volume":"10","author":"Turbyfill","year":"2022","journal-title":"Vaccines"},{"key":"B41","doi-asserted-by":"publisher","first-page":"2002","DOI":"10.1128\/iai.58.6.2002-2004.1990","article-title":"Specific immunoglobulin A-secreting cells in peripheral blood of humans following oral immunization with a bivalent Salmonella typhi-Shigella sonnei vaccine or infection by pathogenic S. sonnei","volume":"58","author":"Van de Verg","year":"1990","journal-title":"Infect Immun."},{"key":"B42","doi-asserted-by":"publisher","first-page":"2950","DOI":"10.1128\/IAI.70.6.2950-2958.2002","article-title":"Construction, characterization, and animal testing of WRSd1, a Shigella dysenteriae 1 vaccine","volume":"70","author":"Venkatesan","year":"2002","journal-title":"Infect. Immun."},{"key":"B43","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/s0022-1759(00)00238-6","article-title":"Multiplexed particle-based flow cytometric assays","volume":"243","author":"Vignali","year":"2000","journal-title":"J. Immunol. Methods."},{"key":"B44","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1128\/JCM.42.5.2031-2035.2004","article-title":"Detection of Shigella by a PCR assay targeting the ipaH gene suggests increased prevalence of shigellosis in Nha Trang, Vietnam","volume":"42","author":"Vu","year":"2004","journal-title":"J. Clin. Microbiol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1016\/j.vaccine.2014.11.049","article-title":"An assessment of enterotoxigenic Escherichia coli and Shigella vaccine candidates for infants and children","volume":"33","author":"Walker","year":"2015","journal-title":"Vaccine"},{"volume-title":"The W.orld Health report 1996; Fighting disease, fostering development. Report of the Director-General","year":"1996","key":"B46"}],"container-title":["Frontiers in Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmicb.2024.1454338\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,6]],"date-time":"2024-09-06T10:26:10Z","timestamp":1725618370000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmicb.2024.1454338\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,6]]},"references-count":46,"alternative-id":["10.3389\/fmicb.2024.1454338"],"URL":"https:\/\/doi.org\/10.3389\/fmicb.2024.1454338","relation":{},"ISSN":["1664-302X"],"issn-type":[{"type":"electronic","value":"1664-302X"}],"subject":[],"published":{"date-parts":[[2024,9,6]]},"article-number":"1454338"}}